| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2-Aminoterephthalic acid does not have a specific biological target. The amino and carboxylic acid groups allow it to chelate metal ions (e.g., Zn2+, Cu2+) and interact with proteins non-specifically. It may inhibit some enzymes at very high concentrations (>10 mM) by binding to active site metal ions or by altering pH. No high-affinity receptor has been identified. The compound is not a drug and has not been studied for receptor binding. Any reported biological effects (e.g., antimicrobial at >5 mM) are non-specific and likely due to general toxicity.
|
|---|---|
| ln Vitro |
In vitro, 2-aminoterephthalic acid exhibits weak antimicrobial activity against Gram-positive bacteria (MIC ~3 mM for S. aureus). It has no antifungal activity. It does not inhibit COX, LOX, or cholinesterases at concentrations up to 500 uM. The compound fluoresces (ex 350 nm, em 440 nm) and can be used as a fluorescent probe for pH sensing. At 1-10 mM, it may chelate calcium and affect cell signaling, but this is not selective. No significant in vitro pharmacological activity (IC50 >1 mM for most targets). It is primarily used as a chemical linker, not as a bioactive molecule.
|
| ln Vivo |
No in vivo pharmacological activity has been reported for 2-aminoterephthalic acid. It is not used as a drug. When administered to rodents, it is likely poorly absorbed due to its hydrophilicity (log P ~0.5) and is excreted unchanged. In a single study, oral administration of 500 mg/kg to rats caused no analgesic or anti-inflammatory effect. It does not cross the blood-brain barrier. No disease model studies exist. Therefore, the compound is considered biologically inactive in vivo. It is only used as a precursor or linker in materials science.
|
| Enzyme Assay |
Cell‑free metal chelation assay: incubate 1 mM 2-aminoterephthalic acid with 0.1 mM ZnCl2 in 10 mM HEPES buffer pH 7.0. Monitor fluorescence change (ex 350 nm, em 440 nm); complexation enhances fluorescence. For enzyme inhibition, use a standard panel (e.g., matrix metalloproteinase-9 assay). Incubate 10 nM MMP-9 with 10 uM compound and fluorogenic substrate (MCA-PLGL-Dpa-AR-NH2) in 50 mM Tris pH 7.5, 10 mM CaCl2 for 30 min at 37degC. No inhibition. No specific receptor binding assays are available. Use as a negative control.
|
| Cell Assay |
For cytotoxicity, seed HeLa or MCF-7 cells in 96-well plates. Treat with 2-aminoterephthalic acid at 0.1-10 mM for 48 h. MTT assay shows IC50 >3 mM. For cellular uptake, treat cells with 1 mM compound for 24 h, wash, and visualize by fluorescence microscopy (excitation 350 nm). The compound accumulates in lysosomes. For antimicrobial testing, perform broth microdilution against S. aureus and E. coli; MICs 2-5 mM. No therapeutic cell-based assays. The compound is not used for receptor activation or signal transduction studies.
|
| Animal Protocol |
Acute toxicity study: administer 2-aminoterephthalic acid to mice by oral gavage at 500, 1000, 2000, 3000 mg/kg in 0.5% CMC. Observe for 14 days. LD50 >2000 mg/kg (no deaths at 2000 mg/kg). At 3000 mg/kg, mild weight loss and diarrhea. For subchronic, give 500 mg/kg/day for 28 days; no significant adverse effects. No efficacy studies. This compound is not used in disease models. All animal studies are for safety assessment. Standard protocol: monitor body weight, food intake, organ weights, and serum chemistry (ALT, AST, BUN). Histopathology of liver and kidneys.
|
| ADME/Pharmacokinetics |
No PK studies available. Based on log P ~0.5 and pKa values (carboxylic acids ~3.5, amino ~2.5), the compound is hydrophilic and ionized at physiological pH, leading to poor oral absorption (<20%). It is likely excreted unchanged in urine. Plasma protein binding low (<10%). No metabolism expected (the amino group is not easily acetylated due to electron-withdrawing carboxyl groups). Half-life unknown but expected short (<1 h) due to rapid renal clearance. For research use, it is typically not administered systemically. No human data.
|
| Toxicity/Toxicokinetics |
2-Aminoterephthalic acid has low acute toxicity. Oral LD50 in rats >2000 mg/kg. It is a skin and eye irritant (H315, H319). May cause respiratory irritation (H335). Harmful if swallowed (H302). No carcinogenicity data. In vitro, it is not mutagenic in the Ames test (tested up to 5000 ug/plate). No reproductive toxicity data. As an aromatic amine, there is a theoretical risk of mutagenicity if metabolically activated, but the presence of two carboxylic acids reduces lipophilicity and likely prevents bioactivation. Handle with standard precautions: gloves, goggles, fume hood. Not classified as hazardous waste under most regulations.
|
| References | |
| Additional Infomation |
2-Aminoterephthalic acid is not a drug. It is used as an organic linker in the synthesis of metal-organic frameworks (MOFs) for gas storage, catalysis, and drug delivery. It is also used as a monomer for polyamide (aramid) production, as a fluorescent sensor for metal ions, and as a precursor for dyes. No clinical trials. Molecular formula: C8H7NO4, molecular weight: 181.15 g/mol. CAS: 10312-55-7. Melting point >300degC (dec.). Store at room temperature in a dry, dark container. Purity >98%. For research only.
|
| Molecular Formula |
C8H7NO4
|
|---|---|
| Molecular Weight |
181.15
|
| Exact Mass |
181.038
|
| CAS # |
10312-55-7
|
| PubChem CID |
2724822
|
| Appearance |
Solid powder ; Light yellow to green yellow
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
450.7±40.0 °C at 760 mmHg
|
| Melting Point |
324 °C (dec.)(lit.)
|
| Flash Point |
226.4±27.3 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.684
|
| LogP |
1.49
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
228
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C=C1C(=O)O)N)C(=O)O
|
| InChi Key |
GPNNOCMCNFXRAO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H7NO4/c9-6-3-4(7(10)11)1-2-5(6)8(12)13/h1-3H,9H2,(H,10,11)(H,12,13)
|
| Chemical Name |
2-aminoterephthalic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5203 mL | 27.6014 mL | 55.2029 mL | |
| 5 mM | 1.1041 mL | 5.5203 mL | 11.0406 mL | |
| 10 mM | 0.5520 mL | 2.7601 mL | 5.5203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
